Deals Of The Week: GSK/Angiochem; GSK/Daiichi Sankyo; Dainippon Sumitomo/Boston Biomedical
Executive Summary
In the latest of a series of rare disease deals, GlaxoSmithKline has forged a collaboration with Montreal-based Angiochem to develop drugs that cross the blood-brain barrier to treat patients with lysosomal storage diseases like Tay-Sachs disease and Fabry disease.